Onemednet CEO Aaron Green recently bought 36,650 shares of OneMedNet Corp (NASDAQ:ONMD) common stock for $21,011, increasing his direct holdings to 1,896,375 shares. This purchase comes as the stock trades near its 52-week low after a 55% decline in six months, despite the company posting 148% revenue growth and significantly reducing liabilities. OneMedNet also secured over $3 million in bookings for 2026 and partnered with Inka Health for oncology data access, while facing a Nasdaq non-compliance notice regarding its minimum bid price.

Synopsys (SNPS) is considered a top big tech stock by Wall Street analysts. Following its fiscal Q1 results, BofA raised its price target to $600 with a Buy rating, citing promising FY26 guidance and potential positive catalysts from an upcoming investor day. Wells Fargo also increased its price target to $535, reiterating an Equal Weight rating, and noted better-than-expected adjusted organic 2026 forecasts.

Edgewell Personal Care rejected a $30-per-share offer from Yellow Wood Partners, leading to a jump in its stock price as the market began to price in the possibility of a higher bid. This event highlights how consumer stocks are diverging, with staples and discretionary spending items moving independently, and how an acquisition offer, even if rejected, can serve as a significant valuation marker for a company.

Culp, Inc. (CULP) is scheduled to announce its Q4'25 earnings on July 1st. The company is expected to report a revenue estimate of $50.13 million and an anticipated EPS of ($0.11) for the quarter. This article provides a historical comparison of reported and estimated revenue and EPS figures for recent quarters.

Teledyne FLIR Defense has secured a $28.8 million contract from U.S. Customs and Border Protection (CBP) to enhance border security operations. The company will supply an advanced version of its Lightweight Vehicle Surveillance System (LVSS) under the Enhanced Mobile Surveillance Capability–Lite (eMSC-L) program. These mobile, multi-sensor platforms, mounted on Ford F-250 pickup trucks, will be deployed primarily along the Southwest border to assist agents in detecting and tracking border activity.

Teledyne FLIR Defense has secured a $28.8 million contract from U.S. Customs and Border Protection to bolster border security operations. The company will deliver an advanced version of its Lightweight Vehicle Surveillance System (LVSS), a mobile, multi-sensor platform designed to enhance situational awareness for Border Patrol agents, primarily along the Southwest border. This system integrates advanced radar and electro-optical/infrared cameras on a rapidly deployable mast, enabling efficient detection and tracking of individuals and vehicles.

S&P Global reported that its US Purchasing Managers' Index (PMI) survey showed a five-month high in private sector output growth in June, with manufacturing nearing a four-year high. Alongside this positive economic indicator, the company confirmed a quarterly cash dividend of $0.97 per share, maintaining its long-standing record of annual dividend increases. This commitment signals management's confidence in future cash flows and the business model, despite potential risks related to capital market conditions and AI investment.

NexMetals Mining Corp. announced a significant update to its Mineral Resource Estimate for the Selkirk Project in Botswana, increasing the contained copper equivalent metal inventory by 63%. The company established 1.1 billion pounds of copper equivalent in the Indicated category and 200 million pounds in the Inferred category, driven by improved metallurgical recoveries, inclusion of additional payable metals, and an expanded mineralized envelope. This update positions Selkirk as a strategically important asset with potential for accelerated development towards pre-feasibility, highlighting its role in NexMetals' future growth.

Astellas' Padcev and Gilead's Trodelvy, both antibody-drug conjugates (ADCs), have received significant EU approvals. Padcev, in combination with Keytruda, is now approved for muscle-invasive bladder cancer as a pre- and post-surgery regimen, while Trodelvy's label has expanded to include first-line treatment for certain triple-negative breast cancer patients. These approvals provide new therapeutic options and are expected to be key growth drivers for the respective products.

Zacks Research recently adjusted its earnings per share estimates for Vail Resorts (NYSE: MTN), slightly increasing Q4 2026 EPS to ($5.29) from ($5.31) and raising some other quarterly forecasts. Despite these minor upward revisions, Zacks maintains a "Strong Sell" rating on the stock, while the broader analyst consensus rates it as a "Hold" with an average price target of $151.45. Vail Resorts recently reported an earnings miss for its latest quarter, though revenue exceeded expectations, and announced a quarterly dividend of $2.22 per share.